Real-world use of disease-modifying therapy in persons with multiple sclerosis aged 55 and over

BackgroundAs the average age of multiple sclerosis (MS) population rises globally, unclear guidelines on disease-modifying therapy (DMT) use in older persons with MS (pwMS) contribute to increased variability in clinical practice. The factors driving DMT utilisation in this population are not well u...

Full description

Saved in:
Bibliographic Details
Published in:BMJ neurology open Vol. 7; no. 2; p. e001108
Main Authors: Stanikić, Mina, Salmen, Anke, Kamm, Christian P, Roth, Patrick, Calabrese, Pasquale, Zecca, Chiara, Gobbi, Claudio, Baum, Claudia, Ineichen, Benjamin Victor, von Wyl, Viktor, Stanikic, Mina, Wyl, Viktor von
Format: Journal Article
Language:English
Published: England BMJ Publishing Group Ltd 23.09.2025
BMJ Publishing Group LTD
BMJ Publishing Group
Subjects:
Age
Citizenship
Clinical medicine
Disease
Education
EPIDEMIOLOGY
Multiple choice
MULTIPLE SCLEROSIS
Older people
Original research
Questionnaires
Self report
Sociodemographics
Variables
Switzerland
MULTIPLE SCLEROSIS
EPIDEMIOLOGY
ISSN:2632-6140, 2632-6140
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundAs the average age of multiple sclerosis (MS) population rises globally, unclear guidelines on disease-modifying therapy (DMT) use in older persons with MS (pwMS) contribute to increased variability in clinical practice. The factors driving DMT utilisation in this population are not well understood. We explored DMT utilisation patterns in pwMS aged 55 and older enrolled in the Swiss MS Registry (SMSR), a nationwide observational study with voluntary participation.MethodsWe conducted an exploratory analysis using data from SMSR participants who had reported DMT status in the most recent follow-up survey and at least once within the previous 3 years. Participants were categorised and compared by current and past DMT use: No DMT (no use), Stopped (prior use), Continued (same DMT), Switcher (changed DMT) and New (initiated DMT). Log-binomial regression identified factors associated with non-use, grouping participants as No DMT (No DMT, Stopped) and DMT (Continued, Switcher, New).ResultsAmong 378 participants (mean age 63.2±6.7 years), 206 (54.5%) reported DMT use: 176 (46.6%) continued the same DMT, 20 (5.3%) switched and 10 (2.6%) newly initiated DMT. Among non-users, 54 (14.3%) had stopped treatment, while the rest did not use DMT during the study period. In participants with regular neurological care, longer MS duration (relative risk (RR)=1.018, 95% CI 1.008 to 1.028) and older age (RR=1.016, 95% CI: 1.001 to 1.032) were associated with higher likelihood of DMT non-use, and participants with primary (RR=1.736, 95% CI: 1.175 to 2.565) and secondary progressive MS (RR=1.423, 95% CI: 1.023 to 1.981) were more likely not to use DMTs compared with relapsing-remitting MS. No significant associations were observed in participants without regular neurological follow-up.ConclusionsDespite unclear efficacy and safety, many older pwMS continue DMT use. Use is primarily associated with relapsing-remitting MS, while age and disease duration show only modest or no association.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2632-6140
2632-6140
DOI:10.1136/bmjno-2025-001108